Loading...
•
Dec 31, 2023
Bioxcel Therapeutics Q4 2023 Earnings Report
Reported financial results for Q4 2023 and provided an update on late-stage clinical programs for BXCL501.
Key Takeaways
BioXcel Therapeutics reported Q4 2023 financial results, including net revenue from IGALMI of $376,000, R&D expenses of $9.9 million, SG&A expenses of $9.6 million, and a net loss of $22.3 million. The company is focusing on advancing its TRANQUILITY and SERENITY clinical programs.
Net revenue from IGALMI was $376,000 for the fourth quarter of 2023, compared to $238,000 for the same period in 2022.
Research and Development (R&D) expenses were $9.9 million for the fourth quarter of 2023, compared to $32.5 million for the same period in 2022.
Selling, General and Administrative (SG&A) expenses were $9.6 million for the fourth quarter of 2023, compared to $20.7 million for the same period in 2022.
BioXcel Therapeutics had a net loss of $22.3 million for the fourth quarter of 2023, compared to a net loss of $54.8 million for the same period in 2022.
Bioxcel Therapeutics
Bioxcel Therapeutics
Bioxcel Therapeutics Revenue by Segment
Revenue by Segment
IGALMI Revenue
CapyFin.com Forward Guidance
The Company estimates that its current cash and cash equivalents will fund its operations through mid-2024.